NEW YORK (GenomeWeb) – HTG Molecular Diagnostics announced today that it has signed a long-term agreement with Thermo Fisher Scientific to develop several in vitro diagnostic tests for use with Thermo Fisher's next-generation sequencing Ion PGM Dx system.
Terms of the deal were not disclosed.
"We believe the combination of HTG EdgeSeq chemistry and automation platform with the Ion Torrent next-generation sequencing platform is a great solution for clinical sequencing workflows in molecular diagnostic laboratories," said HTG CEO TJ Johnson in a statement. "We believe this agreement will provide us important options for our planned diagnostic menu."
In October 2014, HTG struck a similar deal with Illumina to develop IVD diagnostics kits using Illumina's sequencing technology and HTG's Edge platform.
In February, Thermo Fisher signed an agreement with Invivoscribe Technologies to develop multiple next-generation sequencing-based in vitro cancer diagnostics on Thermo's Ion PGM Dx system, as well as associated bioinformatics software for applications in liquid biopsies.